(四氢-硫代吡喃-4-基)-乙酸 | 137103-09-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻烷
• 中文名称: (四氢-硫代吡喃-4-基)-乙酸
• 英文名称: 2-(Thian-4-yl)acetic acid
• CAS: 137103-09-4
• 化学式: C₇H₁₂O₂S
• mdl: MFCD16045905
• 分子量: 160.24
• InChiKey: TXNUYSZERASPCT-UHFFFAOYSA-N

物化性质

• 沸点：
  320.4±15.0 °C(Predicted)
• 密度：
  1.159±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  62.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Acyclic 1,4-Diamines and Uses Thereof
  申请人：Jeong Jae U.

  公开号：US20090105259A1

  公开（公告）日：2009-04-23

  This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain acyclic diamines, which are agonists of TRPV4 channel receptors.

  本发明涉及一种新型化合物，可用于治疗与TRPV4通道受体相关的疾病。更具体地说，本发明涉及某些无环二胺，它们是TRPV4通道受体的激动剂。
• NOVEL BISPHOSPHONIC ACID COMPOUND
  申请人：Fuji Yakuhin Co., Ltd.

  公开号：EP3409679A1

  公开（公告）日：2018-12-05

  It is intended to provide a novel bisphosphonic acid compound or a salt thereof which shows a remarkable inhibitory effect on ectopic calcification, and a pharmaceutical composition comprising the same. The present invention provides a bisphosphonic acid compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof: wherein ------- represents a single bond or a double bond; A represents a saturated cyclic hydrocarbon or a saturated heterocyclic ring comprising a sulfur atom or an oxygen atom; and R1 and R2 each independently represent an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an aryloxy group, a haloalkoxy group, a haloalkyl group, a halogen atom or a hydrogen atom.

  本发明旨在提供一种对异位钙化具有显著抑制作用的新型双膦酸化合物或其盐，以及由其组成的药物组合物。本发明提供了由下式（1）代表的双膦酸化合物或其药学上可接受的盐： 其中 ------- 代表单键或双键；A 代表饱和环状烃或包含硫原子或氧原子的饱和杂环；R1 和 R2 各自独立地代表烷基、烯基、炔基、烷氧基、芳氧基、卤代烷氧基、卤代烷基、卤原子或氢原子。
• Bisphosphonic acid compound
  申请人：FUJIYAKUHIN CO., LTD.

  公开号：US10689408B2

  公开（公告）日：2020-06-23

  It is intended to provide a novel bisphosphonic acid compound or a salt thereof which shows a remarkable inhibitory effect on ectopic calcification, and a pharmaceutical composition comprising the same. The present invention provides a bisphosphonic acid compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof: wherein represents a single bond or a double bond; A represents a saturated cyclic hydrocarbon or a saturated heterocyclic ring comprising a sulfur atom or an oxygen atom; and R1 and R2 each independently represent an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an aryloxy group, a haloalkoxy group, a haloalkyl group, a halogen atom or a hydrogen atom.

  本发明旨在提供一种对异位钙化具有显著抑制作用的新型双膦酸化合物或其盐，以及由其组成的药物组合物。本发明提供了由下式（1）代表的双膦酸化合物或其药学上可接受的盐： 其中代表单键或双键；A 代表饱和环状烃或包含硫原子或氧原子的饱和杂环；R1 和 R2 各自独立地代表烷基、烯基、炔基、烷氧基、芳氧基、卤代烷氧基、卤代烷基、卤原子或氢原子。
• MASP INHIBITORY COMPOUNDS AND USES THEREOF
  申请人：Bayer Aktiengesellschaft

  公开号：US20210246166A1

  公开（公告）日：2021-08-12

  The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.
• US5070187A
  申请人：——

  公开号：US5070187A

  公开（公告）日：1991-12-03